Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
| FATE THERAPEUTICS (NASDAQ: FATE) | Delayed: 2.08 -0.09 (4.15%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.17 | 52 Week High | $4.76 | |||
| Open | $2.13 | 52 Week Low | $1.46 | |||
| Day High | $2.17 | P/E | N/A | |||
| Day Low | $2.01 | EPS | $-1.91 | |||
| Volume | 1,064,419 | |||||
